XML 67 R50.htm IDEA: XBRL DOCUMENT v3.26.1
LICENSE REVENUE - Narrative (Details)
1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
obligation
Dec. 31, 2024
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2020
program
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items            
Nonrefundable, payment   $ 1,300,000 $ 1,300,000      
Maximum potential milestone payments     $ 41,250,000      
Revenue, number of performance obligation, | obligation     1      
Amount allocated to performance obligation   $ 1,300,000        
Total revenue     $ 1,300,000 $ 200,000    
License fee revenue            
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items            
Total revenue     1,300,000 200,000    
2seventy bio, Inc.            
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items            
Development milestone payment receivable         $ 51,500,000  
2seventy bio, Inc. | Initial Programs            
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items            
Number of programs related to collaborative agreement | program           2
Regeneron Pharmaceuticals, Inc. | Initial Programs, Program 3            
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items            
Nonrefundable, upfront payment $ 100,000          
Accounts receivable     200,000      
Regeneron Pharmaceuticals, Inc. | License fee revenue            
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items            
Total revenue     0 $ 200,000    
Scithera License Agreement | License fee revenue            
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items            
Revenue recognized related to performance obligation     $ 1,300,000